Research Interests

Asymmetric synthesis is a cornerstone of modern pharmaceutical research, where the selective production of single enantiomers is crucial for developing highly effective and safer drug molecules. Traditional approaches to asymmetric synthesis include asymmetric chemo-catalysis, chiral pool synthesis, and resolution techniques, with asymmetric chemo-catalysis standing out as the most efficient due to its minimal chiral source requirement. In recent years, biocatalysis has emerged as a powerful and sustainable alternative within this domain, offering unparalleled selectivity, mild reaction conditions, and eco-friendly attributes. Biocatalysts enable highly stereoselective transformations, often outperforming conventional chemical catalysts in terms of specificity and efficiency. Furthermore, protein engineering and directed evolution have expanded the catalytic repertoire of enzymes, allowing the tailoring of biocatalysts to meet synthetic challenges with remarkable precision. 

The fusion of biocatalysis with modern organic synthesis (photochemistry, electrochemistry, etc.) holds immense promise for revolutionizing pharmaceutical and fine chemical industries, paving the way for a more sustainable future in asymmetric synthesis. My future research focuses on the development of novel biocatalytic methodologies for the asymmetric synthesis of bioactive molecules.